[Dopaminergic agents, COMT inhibitors or amantadine? Proper treatment for your Parkinson patient].

Abstract

Over the last six years, eight new substances for the treatment of idiopathic parkinsonism (IP) have been approved for use: four oral and one parenteral dopamine agonist (apomorphine), two COMT-inhibitors and budipine. The old drug amantadine has experienced a renaissance in the treatment of a complication occurring during long-term treatment of IP, namely levodopa-induced dyskinesia. Deep brain stimulation with programmable pulse generators and stereotactically implanted electrodes are increasingly being used in patients with severe on-off phases and levodopa dyskinesia. The treatment of Parkinson's disease unresponsive to dopaminergic substances and that associated with dementia remains problematical. In combinations of parkinsonism and dementia, the cholinesterase inhibitors are being used in particular for Lewy body dementia.

• Authors: A O Ceballos-Baumann
• Journal: MMW Fortschritte der Medizin (MMW Fortschr Med) Vol. Suppl 2 Pg. 37-43 (May 06 2002) ISSN: 1438-3276 [Print] Germany
• Vernacular Title: Dopaminergika, COMT-Hemmer oder Amantadin? Wie Sie Ihren Parkinsonpatienten richtig behandeln.
• PMID: 12070848 (Publication Type: English Abstract, Journal Article)

Chemical References

• Antiparkinson Agents
• Catechol O-Methyltransferase Inhibitors
• Dopamine Agents
• Amantadine

Topics

• Amantadine (adverse effects, therapeutic use)
• Antiparkinson Agents (adverse effects, therapeutic use)
• Catechol O-Methyltransferase Inhibitors
• Dopamine Agents (adverse effects, therapeutic use)
• Drug Therapy, Combination
• Humans
• Long-Term Care
• Neurologic Examination (drug effects)
• Parkinson Disease (diagnosis, drug therapy)
• Treatment Outcome